Lupin debuts in Dow Jones best-in-class indices for ESG performance

The global pharmaceutical company has been featured in both the DJBIC World Index and the DJBIC Emerging Markets Index

Gland Pharma posts record revenue, nearly doubles profit in Q4 FY26

The 38% adjusted EBITDA margin of base business has been supported by robust growth in the CDMO segment

CORONA Remedies posts robust FY26 with 17.3% revenue growth, 33.4% PAT surge

The company highlighted a series of strategic moves during the year, including the acquisition of WOKADINE, marking its entry into the Rs. 648 Cr Povidone Iodine market

Dr. Reddy’s to participate in HSBC, Bank of America investor conferences

Pharma major to engage with institutional investors through group meetings in Mumbai and Singapore during May 2026

China poised to launch world’s first CAR-T therapy for gastric cancer

As per GlobalData, CARsgen’s satri-cel could mark a major breakthrough in solid tumor treatment as competition intensifies

Zydus Lifesciences subsidiary faces Rs 9 million GST demand notice

Company plans to appeal against CGST order related to alleged inadmissible input tax credit claims

RPG Life Sciences reports Rs 707.5 crore revenue in FY26, 8% annual growth

In Q4 FY26, the company reported revenue from operations of Rs 176.9 crore, marking a 23.6% year-on-year growth

Asahi Kasei seals Aicuris acquisition to bolster infectious disease pharma push

The deal the group says marks a decisive push deeper into severe infectious diseases and the build-out of a global specialty pharmaceuticals platform

New diabetes drug UBT251 shows strong phase 2 results in China

Aptar Pharma teams up with COVIRIX Medical to explore next-generation antiviral inhaler

COVIRIX Medical says its broad-spectrum antiviral portfolio has already shown positive virology results against key pandemic threats